Table 1: Change in capillary non-perfusion (CNP) based on fluorescein angiography image characteristics available at baseline and week 100

No. of sectors with ≥ 2 step CNP worsening	Ranibizumab 105 (%)	Aflibercept 96 (%)	Bevacizumab 109 (%)
0	73 (70%)	62 (65%)	86 (79%)
1	11 (10%)	18 (19%)	9 (8%)
2	8 (8%)	6 (6%)	4 (4%)
3	5 (5%)	4 (4%)	3 (3%)
4	4 (4%)	1 (1%)	1(3%)
5	1(1%)	1 (1%)	0(0%)
≥6	3(3%)	4 (4%)	6 (6%)